Lil­ly, Ei­sai and Bio­gen seek more specifics in FDA guid­ance on ear­ly Alzheimer’s dis­ease

Alzheimer’s drug man­u­fac­tur­ers are ask­ing the FDA to give them more clar­i­ty on the dif­fer­ent stages of the dis­ease in com­ments they’ve sub­mit­ted on the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.